STRYKER CORP — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Stryker reported Q2 2026 net sales of $6.6B (up 9.4% YoY; 9.0% organic), with reported EPS of $3.30 (up 44.1%) and adjusted EPS of $3.69 (up 17.9%). Gross margin improved to 68.3% (reported) and adjusted operating margin expanded 170 bps to 27.4%. The company narrowed FY2026 guidance to 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS, citing recovery momentum from the March 2026 cyber incident. MedSurg/Neurotechnology grew 9.7%; Orthopaedics grew 9.1%.
Why this rating
Strong Q2 recovery and margin expansion after cyber disruption; modest guidance raise within context of $144B market cap; solid operational execution but no structural business change.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.